News | Interventional Radiology | February 09, 2016

First Patient Treated With LC Bead LUMI Radiopaque Embolic Bead

Collaborative treatment supported by Philips Live Image Guidance brings new tools to interventional radiologists and oncologists to help treat liver cancer and enhanced patient care

BTG, LC Bead LUMI, radiopaque embolic bead, Philips Healthcare, Live Image Guidance, liver cancer

February 9, 2016 — BTG plc and Royal Philips announced a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI in conjunction with Philips Live Image Guidance. The treatment targeted a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.

Liver cancer is the second leading cause of cancer deaths in the world, and one of the most challenging to treat. Each year, more than 700,000 patients worldwide are diagnosed with liver cancer. Interventional embolization is an option for some patients with tumors that cannot be removed by surgery.

The first patient treated signals the next stage in commercializing next-generation embolic beads, which can be visualized during interventional procedures, allowing enhanced visualization to evaluate completeness of tumor treatment. As a result of the collaboration between BTG and Philips, for the first time doctors will be able to see rather than assume the location of the LC Bead LUMI, in order to deliver their treatment with more confidence when treating liver cancer.

“The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patient’s treatment and hopefully improve targeting accuracy,” said Bradford Wood, M.D., director of the NIH Center for Interventional Oncology and chief of interventional radiology. “It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed. Treating the first patient using LC Bead LUMI in combination with dedicated Philips 2-D X-ray and 3-D CBCT [cone beam computed tomography] image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information.”

By enabling visualization of beads during an embolization procedure, LC Bead LUMI will help embolization technology achieve its full potential. LC Bead LUMI has been developed with revolutionary radiopacity technology in collaboration with Philips that enables real-time visualization of bead location during embolization. The device, supported by Philips Live Image Guidance, has the potential to offer interventional radiologists more control, allowing enhanced visualization to evaluate the completeness of tumor treatment and end-point determination.

LC Bead LUMI was cleared for clinical use in the United States in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead.

BTG and Philips will showcase their advancements in interventional oncology at the upcoming symposium on Clinical Interventional Oncology (CIO), taking place Feb. 6 – 7 in Hollywood, Fla.

For more information: www.btg-im.com, www.philips.com

Related Content

Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cardiac Imaging | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...

Image courtesy of Siemens Healthineers

Feature | CT Angiography (CTA) | September 06, 2018 | Dave Fornell
There have been a few big, recent advancements in cardiac computed tomography angiography (CCTA) imaging technology....
Image courtesy of Philips

Image courtesy of Philips

Feature | Interventional Radiology | July 05, 2018 | By Jeff Zagoudis
On May 14, 2018, First Lady Melania Trump underwent an embolization procedure for what was called a benign kidney...
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | Computed Tomography (CT) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Embolx Announces FDA Clearance of Next-generation Sniper Balloon Occlusion Microcatheter
Technology | Interventional Radiology | June 29, 2018
Embolx Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its next-generation...
Post-Mortem CT Angiography Illuminates Causes of Death
News | CT Angiography (CTA) | June 25, 2018
Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-...
High Prevalence of Atherosclerosis Found in Lower Risk Patients
News | Magnetic Resonance Imaging (MRI) | June 08, 2018
Whole-body magnetic resonance angiography (MRA) found a surprisingly high prevalence of atherosclerosis in people...
Guerbet Launches Pair of Microcatheters for Interventional Radiology Procedures
Technology | Interventional Radiology | May 23, 2018
Guerbet LLC USA announced the upcoming launch of SeQure and DraKon, two novel microcatheters for tumor and vascular...
FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR
Technology | Angiography | May 22, 2018
Pie Medical Imaging announced that clinical data on its CAAS vFFR (Cardiovascular Angiographic Analysis Systems for...
Melania Trump in hospital to undergo an interventional radiology (IR) catheter embolization procedure in her kidneys. Angiogram of a kidney.

First Lady Melania Trump in hospital to undergo an interventional radiology (IR) catheter embolization procedure in her kidneys. The left image is an example of a kidney angiogram to highlight the renal blood vessels during an interventional procedure.

News | Interventional Radiology | May 15, 2018 | Dave Fornell
May 15, 2018 — U.S.